{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"9.9","value":"7.2"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"15.0","value":"13.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"description":"Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the PFS endpoint definition.","dispersionType":"95% Confidence Interval","groups":[{"description":"Investigators choice of Letrozole 2.5 mg po qd continuously, tamoxifen 20mg po bid continuously, paclitaxel 80mg/m2 IV over 1 hr on day 1q 7d, 3 wks on, 1 wk off, Pegylated Liposomal Doxorubicin 40 or 50mg/m2 IV over 1 hr on day 1 q. 28d, Topotecan 4.0mg/m2 over 30 min on day 1,8 and 15 of a 28 day cycle. For each arm, 1 cycle - 28 days","id":"OG000","title":"Arm A - Control Arm"},{"description":"Trametinib 2 mg po daily continuous treatment, For each arm, 1 cycle = 28 days","id":"OG001","title":"Arm B - Experimental Arm"}],"paramType":"MEDIAN","populationDescription":"All randomized patients","reportingStatus":"POSTED","timeFrame":"Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}